No Data
Henan taloph pharmaceutical stock (600222.SH): The proportion of shares indirectly controlled by shanghai land increased to 8.71%.
On December 9, Gelonghui reported that Henan Taloph Pharmaceutical Stock (600222.SH) announced it had received a notice from shareholders Zhongsheng Industrial regarding changes in equity. During this period, its indirect shareholder Shanghai Landu Health Industry Investment Management Co., Ltd. (referred to as "Shanghai Landu") gained control of Zhongsheng Industrial's shareholders Gongyi City Zhulin Jinzhu Trading Co., Ltd. (referred to as "Jinzhu Trading") and Gongyi City Zhulin Litian Technology Development Co., Ltd. (referred to as "Litian Technology") due to an agreement, resulting in an increase in the proportion of shares indirectly controlled by Shanghai Landu in the company from 0% to 8.71%. This change in equity does not trigger a mandatory takeover offer and does not involve the company's control.
henan taloph pharmaceutical stock (600222.SH) plans to distribute 0.1 yuan per 10 shares in the first three quarters, with ex-rights and ex-dividends on December 9.
henan taloph pharmaceutical stock (600222.SH) announced that the company plans to distribute 1 share for every 10 shares to all shareholders in the first three quarters of 2024...
Solid Earnings May Not Tell The Whole Story For Henan Taloph Pharmaceutical StockLtd (SHSE:600222)
Tailong Pharmaceutical Report for the Third Quarter of 2024
Henan Taloph Pharmaceutical Stock (600222.SH): The net income for the first three quarters was 28.8959 million yuan, a year-on-year increase of 270.72%.
On October 24, Gelonhui reported that Henan Taloph Pharmaceutical Stock (600222.SH) released its third quarter report for 2024, with the company's revenue for the first three quarters of the year at 1.341 billion yuan, a 7.08% year-on-year decrease; net income attributable to shareholders of the listed company was 28.8959 million yuan, a 270.72% year-on-year increase; net income attributable to shareholders of the listed company after deducting non-recurring gains and losses was 19.4868 million yuan, a 181.61% year-on-year increase; and the basic earnings per share was 0.0519 yuan.
henan taloph pharmaceutical stock (600222.SH): Currently, products such as Huoxiang Zhengqi Formula, Wuzi Yanzong Oral Liquid, and Shengmai Yin have all been successfully launched for production.
On October 8th, Henan Taloph Pharmaceutical Stock (600222.SH) stated in a recent performance briefing that the company adheres to the operation philosophy of being an expert in traditional chinese medicine oral liquids, market-driven, and in recent years has continuously increased the production of chinese patent medicine products through product introduction, research on classic formulas, and development of drugs with the same name and formula, promoting the diversified development of products and constructing a scientific product portfolio. Currently, products introduced such as the Huoxiang Zhengqi mixture, Wuzi Yanzong oral liquid, Shengmai Yin, have all been successfully launched for production.
Why Investors Shouldn't Be Surprised By Henan Taloph Pharmaceutical Stock Co.,Ltd's (SHSE:600222) 30% Share Price Plunge
